Arca Biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company’s main product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator that the company intends to evaluate in a new clinical trial for the treatment of atrial fibrillation (AF), in patients with heart failure and left ventricular dysfunction (HFREF). Strategy The company’s mission is to become a biopharmaceutical company developing cardiovascular therapies with an emphasis on genetically-targeted therapies. To achieve this goal, the company is pursuing the following strategies: advance the development of Gencaro. The company plans to focus its efforts on initiating and completing the GENETIC-AF Trial; raise substantial additional funding or complete a strategic transaction; build a cardiovascular pipeline; and leverage its existing assets. Research and Development The company’s research and development expenses totaled $1.1 million, as of December 31, 2012. Significant Events In November 2013, ARCA biopharma, Inc. (ARCA) entered into a Clinical Research Agreement with Duke University’s Duke Clinical Research Institute (DCRI), to serve as the coordinating center and principal investigator for GENETIC-AF (the Study), a planned Phase 2B/3 genetically-targeted, comparative effectiveness clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for the prevention of atrial fibrillation in patients with heart failure.
arca biopharma inc (ABIO:NASDAQ CM)
11080 CirclePoint Road
Westminster, CO 80020
|No competitor information is available for ABIO.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ARCA BIOPHARMA INC, please visit www.arcabiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.